Renee Ned-Sykes

Renee Ned-Sykes

Auto-generated profile, based on publicly available information

Renee Ned-Sykes

Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Developmental Cell
Verified
Journal Article
Closed access
JLJau Yi Li
Jau Yi Li
NPNeal Paragas
Neal Paragas
RNRenee M. Ned
Renee M. Ned
AQAndong Qiu
Andong Qiu
MVMelanie Viltard
Melanie Viltard
JBJonathan Barasch
Jonathan Barasch

19 May 2008 in Malaria Journal
Verified
Journal Article
Open access
PDF file
VJVidhan Jain
Vidhan Jain
HAHenry B Armah
Henry B Armah
JTJon E Tongren
Jon E Tongren
RNRenée M Ned
Renée M Ned
NWNana O Wilson
Nana O Wilson
JSJonathan Kwamina Stiles
Jonathan Kwamina Stiles
Background: Plasmodium falciparumin a subset of patients can lead to cerebral malaria (CM), a major contributor to malaria-associated mortality. Despite treatment, CM mortality can be as high as 30%, while 10% of survivors of the disease may experience short- and long-term neurological complications. The pathogenesis of CM is mediated by alterations in cytokine and chemokine homeostasis, inflammation as well as vascular injury and repair processes although their roles are not fully understood. The hypothesis for this study is that CM-induced changes in inflammatory, apoptotic and angiogenic factors mediate severity of CM and that their identification will enable development of new prognostic markers and adjunctive therapies for preventing CM mortalities.Methods: Plasma samples (133) were obtained from healthy controls (HC, 25), mild malaria (MM, 48), cerebral malaria survivors (CMS, 48), and cerebral malaria non-survivors (CMNS, 12) at admission to the hospital in Jabalpur, India. Plasma levels of 30 biomarkers ((IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic protein, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1 (MCAF), MIP-1α, MIP-1β, RANTES, TNF-α, Fas-ligand (Fas-L), soluble Fas (sFas), soluble TNF receptor 1 (sTNF-R1) and soluble TNF receptor 2 (sTNFR-2), PDGF bb and VEGF)) were simultaneously measured in an initial subset of ten samples from each group. Only those biomarkers which showed significant differences in the pilot analysis were chosen for testing on all remaining samples. The results were then compared between the four groups to determine their role in CM severity.Results: IP-10, sTNF-R2 and sFas were independently associated with increased risk of CM associated mortality. CMNS patients had a significantly lower level of the neuroprotective factor VEGF when compared to other groups (P < 0.0045). The ratios of VEGF to IP-10, sTNF-R2, and sFas distinguished CM survivors from non survivors (P < 0.0001).Conclusion: The results suggest that plasma levels of IP-10, sTNF-R2 and sFas may be potential biomarkers of CM severity and mortality. VEGF was found to be protective against CM associated mortality and may be considered for adjunctive therapy to improve the treatment outcome in CM patients.

15 November 2003 in Blood
Verified
Journal Article
Closed access
PDF file
RNRenée M. Ned
Renée M. Ned
WSWojciech Swat
Wojciech Swat
NANancy C. Andrews
Nancy C. Andrews
Transferrin receptor (TfR) facilitates cellular iron uptake by mediating endocytosis of its ligand, iron-loaded transferrin. Although TfR is widely believed to be important for iron acquisition by all mammalian cells, direct experimental evidence is lacking. We have previously shown that mouse embryos homozygous for a disrupted transferrin receptor allele (TfR-/-) die of anemia before embryonic day 12.5, although most other embryonic tissues appear to be developing normally. Here, we have investigated the importance of TfR postnatally, by using TfR-/- embryonic stem cells to produce chimeric animals. We find that TfR-/- embryonic stem cells give rise to most tissues and organs, but do not contribute to hematopoietic tissues on a wild-type C57BL/6J background, indicating that both adult erythropoiesis and lymphopoiesis require TfR. On an immunodeficient RAG2-/- background, TfR-/- B-cell development proceeds at least to the IgM+ stage, although significantly fewer IgM+ cells are present in peripheral lymphoid organs. Conversely, T cells lacking TfR are arrested very early in their development, at the CD4-8-3- stage. These results indicate that TfR is necessary for the normal maturation of thymocytes, but that B-cell development is less severely affected by the absence of TfR. (Blood. 2003;102:3711-3718)

31 August 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ACAlan C. Chen
Alan C. Chen
ADAdriana Donovan
Adriana Donovan
RNRenee Ned-Sykes
Renee Ned-Sykes
NANancy C. Andrews
Nancy C. Andrews
Significance: Transferrin receptor 1 (Tfr1) facilitates cellular iron acquisition by binding to and internalizing iron-loaded transferrin. Although this function is essential for red blood cell precursors, the role of Tfr1 in nonhematopoietic tissues has not been thoroughly studied. In this study, we investigated the role of Tfr1 in the intestine by developing mutant mice in which Tfr1 is inactivated specifically in the intestinal epithelium. We discovered that inactivation of Tfr1 has pleiotropic consequences leading to the loss of intestinal epithelial proliferation and homeostasis and induction of genes involved in epithelial–mesenchymal transition. These effects are not related to the iron uptake, revealing a surprising role for this ubiquitous membrane protein.

22 March 2011 in PLoS Currents
Verified
Journal Article
Open access
PDF file
RNRenée M. Ned
Renée M. Ned
SMStephanie Melillo
Stephanie Melillo
MMMichael Marrone
Michael Marrone
Colorectal cancer is the third most common cancer and the second leading cause of cancer-related deaths in the United States. Screening has been shown to be effective in reducing colorectal cancer incidence and mortality. Colonoscopy, sigmoidoscopy, and fecal occult blood tests are all recommended screening tests that have widespread availability. Nevertheless, many people do not receive the evidence-based recommended screening for colorectal cancer. Additional stool-based methods have been developed that offer more options for colorectal cancer screening, including a variety of fecal DNA tests. The only fecal DNA test that is currently available commercially in the United States is ColoSure(TM), which is marketed as a non-invasive test that detects an epigenetic marker (methylated vimentin) associated with colorectal cancer and pre-cancerous adenomas. We examined the published literature on the analytic validity, clinical validity, and clinical utility of ColoSure and we briefly summarized the current colorectal cancer screening guidelines regarding fecal DNA testing. We also addressed the public health implications of the test and contextual issues surrounding the integration of fecal DNA testing into current colorectal cancer screening strategies. The primary goal was to provide a basic overview of ColoSure and identify gaps in knowledge and evidence that affect the recommendation and adoption of the test in colorectal cancer screening strategies.

8 October 2008 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MCMan-Huei Chang
Man-Huei Chang
MLMary Lou Lindegren
Mary Lou Lindegren
MBMary A. Butler
Mary A. Butler
SCStephen J. Chanock
Stephen J. Chanock
NDNicole F. Dowling
Nicole F. Dowling
FGfor the CDC/NCI NHANES III Genomics Working Group
for the CDC/NCI NHANES III Genomics Working Group
Population-based allele frequencies and genotype prevalence are important for measuring the contribution of genetic variation to human disease susceptibility, progression, and outcomes. Population-based prevalence estimates also provide the basis for epidemiologic studies of gene–disease associations, for estimating population attributable risk, and for informing health policy and clinical and public health practice. However, such prevalence estimates for genotypes important to public health remain undetermined for the major racial and ethnic groups in the US population. DNA was collected from 7,159 participants aged 12 years or older in Phase 2 (1991–1994) of the Third National Health and Nutrition Examination Survey (NHANES III). Certain age and minority groups were oversampled in this weighted, population-based US survey. Estimates of allele frequency and genotype prevalence for 90 variants in 50 genes chosen for their potential public health significance were calculated by age, sex, and race/ethnicity among non-Hispanic whites, non-Hispanic blacks, and Mexican Americans. These nationally representative data on allele frequency and genotype prevalence provide a valuable resource for future epidemiologic studies in public health in the United States.